The 12th meeting of the 11th board of directors and the 11th meeting of the 10th board of supervisors held to review and approve the annual work report and other relevant proposals
Release time:
2023-04-21
General Manager's report pointed out that in 2022, my country's macroeconomic policy will adhere to the general tone of seeking progress while maintaining stability. The annual GDP was 121.02 trillion billion yuan, an increase of 3.0 percent over last year (data source: National Bureau of Statistics). Centering on the general policy of "reform, breakthrough, innovation and development", the company strives to maintain the orderly development of various production and operation work, achieving operating income of 3.56 billion yuan for the whole year, a decrease of 6.43 percent over the same period last year, and net profit attributable to shareholders of 0.288 billion yuan, a decrease of 68.86 percent over the same period last year. By the end of 2022, the company's total assets were 7.321 billion billion yuan, up 4.22 percent year-on-year, and the net assets attributable to shareholders of listed companies were 5.186 billion billion yuan, down 0.41 percent year-on-year.
2022
, the company's industrial chain extension war made new progress. The company set up Yunnan Jianfeng New Building Materials Co., Ltd. to promote its aggregate, machine sand and other projects in an orderly manner, and Yunnan Jianfeng invested 0.133 billion yuan to increase the capital of its subsidiary Jianfeng Exhibition, making it a holding enterprise of the company, and the company's cement business sector has been further developed.
Facing the unfavorable external environment, the company's cement companies continue to implement benchmarking and refined management, steadily implement various technical reforms, strictly control production costs, strive to overcome the pressure of declining demand, and actively expand the sales market. Daye Peak has improved the overall production capacity of the kiln system through technical transformation and operation process optimization of grate cooler, packaging machine and kiln cylinder, combined with the use of MES system for optimal parameter traceability. Actively develop new agents, open up new markets, strengthen cooperation with large enterprises, undertake key projects, effectively cope with the overall weak cement market and maintain the balance of production and sales; vigorously promote the construction of green mines and green factories, and successfully entered the list of national green factories in 2022. Yunnan Jianfeng has strengthened the technological transformation of energy saving and consumption reduction, reformed the kiln head sealing device, grate cooler and other equipment, and improved the kiln output. The dust collector at the bottom of the cement blending warehouse has been added, and the feeding device of the roller press has been reformed, effectively improving the production site environment. Actively implement the brand strategy, adhere to the "direct sales + agent" dual-track sales model, while effectively reducing the sales cost while maintaining the advantages of multi-channel sales. Huang Ping Jianfeng actively studied, explored and applied advanced technology to tackle key problems. Through the transformation of the cone under the decomposition furnace to reduce negative pressure fluctuation, replace the high-temperature feed lock valve, and increase the snowman pushing device of the grate cooler, the stability of the equipment has been improved. Facing the unfavorable demand situation, it actively undertakes key projects externally and strengthens the business skills training of the marketing team internally, with Kaili and Huang Ping as the core markets, maintain the leading sales of the same type of kiln line in the region.2022
, the company's pharmaceutical sector technical reform and engineering construction continued to advance, innovation and research and development to make new progress. Jianfeng Pharmaceutical's annual production of 2 billion tablets of solid preparations (international project) has completed the completion acceptance of construction projects, equipment installation and debugging, certified product registration batch production, completed the human bioequivalence test, submitted registration materials, and entered the waiting stage of cGMP application for certification; jinxi Production Base has completed the completion and acceptance of the technical transformation project of bulk drugs, completed the installation and debugging of the newly added RTO incineration treatment facilities, completed the automatic transformation of the packaging equipment of freeze-dried powder injection and solid preparation production line, and completed the transformation of the refrigeration system of the raw material workshop and the comprehensive preparation building. The construction of the single-dose eye drop production line of Jianfeng Pharmaceutical has also been basically completed and has entered the stage of product stability inspection. The 205 and 206 workshops of Anhui Xinbeika Phase II Project have been completed and put into trial production. The chlorine dioxide workshop has completed the information control transformation and improved the safety guarantee level. The technical renovation project of Moxi Xiaohuan and pharmaceutical intermediates in Jianfeng Beika 102 Workshop has been completed and put into trial operation. The 203, 205 and 206 workshops have been completed and have entered the stage of production plan review. Jianfeng Pharmaceutical and its subsidiaries further increased investment in research and development, continued to promote the phase I clinical trials of the new anti-tumor drug DPT and JFAN-1001 project, and completed the application for production registration of several products such as fluprost eye drops, single-dose sodium hyaluronate eye drops, and mycophenolate mofetil capsules. At present, 11 drugs (including consistency evaluation) have been submitted to the State Drug Administration for production registration.
On the same day, the company also held the 11th meeting of the 10th Board of Supervisors, and reviewed and approved 5 related reports and proposals including the 2022 Board of Supervisors Report of the company. (residual fruit)
More information
Publicity of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project of daye peak cement co., ltd. According to the requirements of the Interim Measures for Environmental Protection Acceptance for Completion of Construction Projects (No.4 [2017] of the State Environmental Regulations) issued by the Ministry of Environmental Protection, the environmental protection acceptance information of "Kiln End Flue Gas Desulfurization Project" of daye peak cement co., ltd. is now publicized. Basic Information of 1. Project Project Name: Kiln End Flue Gas Desulfurization Project Construction Unit: daye Jianfeng Cement Co., Ltd. Project Construction Location: Yongguang Village, Baoan Town, daye city, nature of the project in the existing plant area of daye Jianfeng Cement Co., Ltd.: The construction content of the technological transformation project is: This technological transformation project is mainly to build a wet desulfurization system for kiln end gas of the company's existing 4000t cement clinker production line, adopting limestone-gypsum wet flue gas desulfurization process. The project covers a total area of 500 m2, with a new construction area of about 450 m2. It mainly builds desulfurization complex building, flue gas system, SO2 absorption system, limestone powder conveying and limestone slurry preparation system, process water system, gypsum dehydration system and supporting pipelines. Power supply, water supply, compressed air and other public works rely on the existing plant. Total investment and environmental protection investment: the total investment of the project is 10.37 million yuan, all of which are environmental protection investment. The project was entrusted to Huangshi Yangtze River Environmental Engineering Design and Research Institute to carry out environmental impact assessment in September 2017. On November 16, 2017, Daye Municipal Environmental Protection Bureau issued a reply with YEHAN [2017] No. 354. Implementation of 2. environmental protection measures The scope of this acceptance is the flue gas desulfurization system and supporting facilities at the end of the kiln. (1) Exhaust gas pollution
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Contact Us
No. 88 Wujiang East Road, Jinhua City, Zhejiang Province, China
Tel: +86-579-82326868
Fax : +86-579-82324666
©2023 Zhejiang Jianfeng Group Co., Ltd. Powered by: www.300.cn SEO Business License
SAF Coolest v1.2 设置面板 SHJSS-AHDB-FSSQE-ZSW
无数据提示
Sorry, the current column has no content !
You can view other columns or return to Home Page